Inside the 30-Month Health Status Numbers
A new analysis of a completed phase 3 trial reports that patients with a frequently missed form of heart disease held onto more of their daily function over two and a half years when treated with an oral drug, though their function still declined.
The finding comes from a secondary analysis of the ATTRibute-CM trial, published in JAMA Cardiology and summarized by The American Journal of Managed Care. Investigators evaluated 611 adults with symptomatic transthyretin amyloid cardiomyopathy, randomized two to one to oral acoramidis or matching placebo for 30 months.
The measure was the Kansas City Cardiomyopathy Questionnaire Overall Summary score, a 0 to 100 patient-reported scale covering symptoms, physical function, and quality of life. By month 30, scores had fallen 11.5 points on acoramidis and 21.4 points on placebo. The difference of 9.9 points, with a confidence interval of 6.0 to 13.9, was statistically significant.
The direction matters more than the number. Both groups got worse. One group got worse more slowly. The researchers wrote that acoramidis "attenuated the decline in patient-reported health status vs placebo."
Group differences appeared within the first three months and reached statistical significance after month nine. Using combined survival and health status categories, 46.6 percent of acoramidis recipients were alive and not measurably worse at 30 months, compared with 29.8 percent on placebo.
A Diagnosis That Often Arrives Late
Transthyretin amyloid cardiomyopathy, usually shortened to ATTR-CM, occurs when a blood protein called transthyretin loses its stable four-part structure, misfolds, and deposits as amyloid fibrils in the heart muscle. The muscle stiffens. Filling pressures rise. Heart failure follows and progresses.
The condition is underdiagnosed for a mundane reason. Its early presentation looks like ordinary heart failure in an older adult, with breathlessness, fatigue, swelling, and exercise intolerance. It occurs in a wild-type form linked to aging and in a variant form driven by inherited mutations in the transthyretin gene.
Diagnosis typically requires a bone-tracer scan, blood and urine testing to rule out a different amyloid protein, and in some cases genetic testing or biopsy. Patients often see several specialists first. Non-cardiac clues, including carpal tunnel syndrome years earlier and spinal stenosis, are common but easy to file away as unrelated.
Acoramidis, sold as Attruby, was approved by U.S. regulators in November 2024 to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM. It stabilizes the transthyretin tetramer so it dissociates less readily. The primary trial results, and a follow-up analysis of mortality and hospitalization published in the Journal of the American College of Cardiology, established that earlier benefit. The new work asks a different question: whether patients could feel the difference.
The Price Tag and the Prior Authorization Hurdle
Access is where this lands for households. Acoramidis carries a list price of $18,759 per month, according to the AJMC summary. List price is not what most insured patients pay, but it sets the terms of every coverage negotiation that follows.
Payers typically require documentation before approving a first fill. Published state Medicaid criteria illustrate what that looks like in practice. Minnesota's prior authorization criteria require a confirmed diagnosis through scintigraphy, biopsy, or genetic testing; New York Heart Association class I through III heart failure; clinical manifestations of cardiomyopathy; and specialist involvement in prescribing.
The practical consequence is that the diagnostic workup is not merely a clinical step. It is a coverage prerequisite. Patients who suspect amyloidosis but have not completed imaging or genetic testing will not clear prior authorization regardless of symptoms.
Nothing in this analysis changes eligibility, dosing, or approved use. Patients on acoramidis, tafamidis, or any other therapy should not adjust or stop anything based on a news report. Questions about whether a specific regimen still fits belong with the treating cardiologist.
Reading the Limits of a Secondary Analysis
Several limitations are worth stating plainly rather than burying.
This is a prespecified secondary outcome from a trial whose primary results were reported earlier. Secondary analyses are hypothesis-supporting rather than hypothesis-testing, and they carry the enrollment characteristics of the original trial.
The investigators noted that ATTRibute-CM eligibility criteria may limit how far the findings generalize. The trial enrolled relatively few women, and relatively few patients with the variant form of the disease, and health status trajectories may differ in those groups. Questionnaire assessments were added through a protocol amendment, so not every participant had a month-three reading.
A sensitivity analysis excluding participants who started tafamidis after month 12 produced a similar 9.7-point difference, which argues the result was not driven by crossover treatment. Benefits were consistent across prespecified subgroups including genotype, age, sex, and heart failure class.
The trial was industry sponsored. Acoramidis is manufactured by BridgeBio Pharma.
Coming Decisions for Patients and Payers
Real-world data are accumulating separately. A non-interventional study following acoramidis use in routine clinical practice, registered as ACO-REAL, is recruiting with estimated primary completion in April 2028. That is the kind of evidence that tends to shape formulary decisions once trial populations meet ordinary practice.
For families, the near-term action is diagnostic rather than pharmaceutical. Older adults with unexplained heart failure, especially those with a history of carpal tunnel release or unexplained thickening on echocardiogram, can ask their cardiologist directly whether amyloidosis has been ruled out.
The confirmed finding is that a stabilizer drug slowed the loss of daily function over 30 months in a trial population. The people most affected are older adults already diagnosed with ATTR-CM and those still undiagnosed. The reasonable step is asking about the workup, not asking for the prescription. The central uncertainty is how the result holds in women, in variant disease, and in patients who would never have qualified for the trial.
Frequently Asked Questions
What did the new analysis actually find? Over 30 months, patient-reported health status declined less in the acoramidis group than in the placebo group, a difference of 9.9 points on a 100-point scale. Both groups declined.
Does slowing decline mean patients got better? No. Average scores fell in both arms. About a quarter of acoramidis recipients were classified as alive and improved, compared with roughly 14 percent on placebo.
What is ATTR-CM and why is it missed? It is a form of heart failure caused by amyloid protein deposits in the heart muscle. It is missed because early symptoms resemble common heart failure in older adults.
Is this a new drug approval? No. Acoramidis was approved in 2024. This analysis reports an additional prespecified outcome from the trial that supported that approval.
Who was not well represented in the trial? Women and patients with the inherited variant form of the disease were enrolled in relatively small numbers, so the findings may apply less confidently to them.
What does the drug cost? The reported list price is $18,759 per month. What an individual pays depends on insurance, and coverage usually requires documented diagnostic confirmation first.
What should patients do with this information? Nothing on their own. Do not start, stop, or change any heart medication based on a news article. Bring questions about diagnosis or treatment to a cardiologist.
